Astragaloside derivative and preparation method and application thereof

A technology for a drug and methylamine, applied in the field of medicine, can solve the problems of many side reactions in the synthesis route, no prodrug properties, and two sugar chains are easy to fall off, so as to achieve improved druggability, less side reactions, and increased water solubility. Effect

Active Publication Date: 2017-05-10
CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
View PDF6 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the many active reaction sites of astragaloside IV: it involves the protection and deprotection of nine hydroxyl groups of three different types: primary, secondary and tertiary; the two sugar chains are easily detached during the reaction; Both the propane structure and the THF ring structure are very easy to open the ring, therefore, so far there is no practical method to prepare water-soluble derivatives of astragalo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Astragaloside derivative and preparation method and application thereof
  • Astragaloside derivative and preparation method and application thereof
  • Astragaloside derivative and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0026] Example 1

[0027] This example provides a method for preparing the compound with the structure of Formula 1 and its structure identification according to claim 1:

[0028] (1) Compound preparation: Take 100 mg of astragaloside IV, add it to 500 mL of 10% pyridine, add 25 mg of sodium bromide, 5 mg of 2,2,6,6-tetramethylpiperidine-1-oxy radical, 1mL of sodium hypochlorite, react at 0℃ for 120min, filter, and adjust the pH to 3 for the filtrate with concentrated hydrochloric acid. After the solid precipitates, concentrate to 20mL, separate solid and liquid, dissolve and transfer the solid with methanol, and concentrate to dryness to obtain 89.7mg of white powder. A compound having the structure of Formula 1 (HPLC purity 98.8%).

[0029] (2) Structure identification:

[0030] White amorphous powder; sprayed with 5% concentrated sulfuric acid / ethanol after TLC development, it shows purple red; (c, 1.0, MeOH); IR (KBr): Vmax: 3417, 2968, 1732, 1621, 1378, 1156, 1066, 1045cm -1 . ...

Example Embodiment

[0038] Example 2

[0039] This example provides a method for preparing the compound with the structure of Formula 1 according to claim 1. The difference compared with Example 1 is that the ratio of solvent and reagent is adjusted:

[0040] Take 100mg of astragaloside IV, add it to 50mL of water, add 25mg of sodium bromide, 10mg of 2,2,6,6-tetramethylpiperidine-1-oxy radical, 0.25mL of sodium hypochlorite, and react at 20℃ 120min, filter, adjust the pH of the filtrate with concentrated hydrochloric acid to 2, after the solids are separated out, concentrate to 10mL, separate the solids and liquids, dissolve and transfer the solids with ethanol, and concentrate to dryness to obtain 91.3mg of white powder, which is the compound with the structure of Formula 1 (HPLC purity 99.1%).

Example Embodiment

[0041] Example 3

[0042] This example provides a method for preparing the compound with the structure of Formula 1 according to claim 1. The difference compared with Example 1 is that the ratio of solvent and reagent is adjusted:

[0043] Take 100mg of astragaloside IV and add it to 10mL of 10% DMF, add 20mg of sodium bromide, 8mg of 2,2,6,6-tetramethylpiperidine-1-oxyl radical, and 0.20mL of sodium hypochlorite. React at ℃ for 120 min, filter, and adjust the pH to 3 with concentrated hydrochloric acid for the filtrate. After the solids are separated out, concentrate to 10mL, separate the solid and liquid, dissolve and transfer the solids with ethanol, and concentrate to dryness to obtain 82.7mg of white powder, which has the structure of formula 1. Compound (HPLC purity 97.9%).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an astragaloside water-soluble derivative, namely astragaloside acid or medicinal salt, ester and amide of the astragaloside acid, with the structure shown in the formula 1. According to the defects that water solubility of astragaloside is poor, so that bioavailability of astragaloside is affected, and astragaloside cannot be developed into a single-component medicine, special alcoholic hydroxyl groups in astragaloside molecules are directionally oxidized into carboxyl groups ingeniously, and the astragaloside water-soluble derivative, namely astragaloside acid is prepared. A preparation method is simple in step, mild in reaction condition, small in side reaction, high in yield, easy to implement and suitable for large-scale production. The astragaloside water-soluble derivative, namely astragaloside acid or medicinal salt, ester and amide of the astragaloside acid, with the structure shown in the formula 1 has a protective function on hypoxia injuries of cardiac muscle cells cultured in vitro, and can be used for preventing and/or treating relevant cardiovascular diseases. The formula 1 is defined in the description.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a preparation method and application of an astragaloside IV derivative, astragalinic acid, or a pharmaceutically acceptable salt, ester and amide thereof, which has the activity of preventing and treating cardiovascular diseases. Background technique [0002] Astragaloside IV is one of the main active components of the traditional Chinese medicine Astragalus membranaceus, and it is also the qualitative and quantitative index component of various traditional Chinese medicine compound preparations in the "Chinese Pharmacopoeia". Pharmacological studies have shown that astragaloside IV has various effects such as improving cardiopulmonary function, enhancing body immunity, anti-virus, and anti-stress (Ren S, et al.Pharmacological effects of Astragaloside IV: a literature review.Journal of Traditional Chinese Medicine , 2013, 33(3):413-416). Although astragaloside IV ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07J53/00A61K31/704A61P9/00A61P9/10
CPCC07J53/004
Inventor 青琳森丁立生彭树林李帮经梁健
Owner CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products